SpyGlass Pharma Inc (SGP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$34.08-1.07%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SGP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Document Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatopros…
Stated in 2 of 2 supplied quarters. Management reported: “Document Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.” “Document Exhibit 99.1 SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Document Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatopros…”
“Document Exhibit 99.1 SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost…”
• Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.
Stated in 2 of 2 supplied quarters. Management reported: “• Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.” “• Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.”
“• Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.”
“• Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.”
• Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.
Stated in 2 of 2 supplied quarters. Management reported: “• Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.” “• Cash, cash equivalents and short-term investments of $251.0 million on March 31, 2026, are expected to fund planned operations through 2028.”
“• Cash, cash equivalents and short-term investments of $234.2 million on June 30, 2026, are expected to fund planned operations through 2028.”
“• Cash, cash equivalents and short-term investments of $251.0 million on March 31, 2026, are expected to fund planned operations through 2028.”
This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma.
Stated in a supplied disclosure. Management reported: “This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma.” ““The acquisition of AVS for SpyGlass Pharma is strategically important as it secures our long-term supply of world class IOLs,” said Patrick Mooney, CEO of SpyGlass Pharma.”
Use available cash and IPO proceeds to fund planned operations through 2028 while advancing the company's programs.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.